Kornimate/medical-research-clean huggingface dataset:
whole-course immunonutrition combined with chemoradiotherapy±icis for local advanced patients with inoperable esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma; Chemoradiotherapy; Immunonutrition; Inoperable

Summary: chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. the goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±icis for local advanced patients with inoperable esophageal squamous cell carcinoma. the main questions it aims to answer are: • if the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±icis is better. • if the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±icis is longer. the experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.


Eligibility criteria:
inclusion criteria: * 18-85 years old; * eastern cooperative oncology group (ecog) 0-2; * esophageal squamous cell carcinoma; * ct2-4an0-3m0 (ajcc 8th) confirmed by radiological examination; * initial unresectable at initial diagnosis confirmed by thoracic surgeons; * treatment naive; * no contraindications for adjuvant chemoradiotherapy; * signature of inform consent. exclusion criteria: * younger than 18 years old or older than 85 years old; * ecog\>2; * esophageal adenocarcinoma, small-cell cancer and other pathological types; * ct1anynm0, ct4banynm0, c anytanynm0 confirmed by radiological examination; * resectable at initial diagnosis confirmed by thoracic surgeons; * previous treatment of chemotherapy, radiotherapy, and other treatment; * contraindications for chemoradiotherapy; * no signature of inform consent.
the influence of non-carious cervical lesions on root coverage

Conditions: Gingival Recession

Summary: the goal of this prospective cohort study is to evaluate the effect of non-carious cervical lesions (nccls) on the outcome of root coverage therapy. the main question it aims to answer is: in gingival recessions associated with nccls, characterized by an undetectable cemento-enamel junction (cej), reconstruction of the cej with a cervical composite restoration, prior to root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft (caf+ctg), provides similar clinical and patient-reported outcomes, as compared to the treatment of gingival recessions associated with nccls, characterized by a visible cej, with root coverage surgery only, by means of a caf+ctg. in nccls where the cej is undetectable (b-type defect), the cej will be reconstructed before surgery with a cervical composite restoration mimicking the anatomic features of the contralateral, homologous tooth. caf+ctg treatment will be performed in all cases. participants will be assessed at 6 weeks, 3 months, and 6 months to evaluate clinical, volumetric, and patient-centred outcomes.

in this investigation, a prospective cohort study, several key outcomes will be assessed. first, we seek to determine whether restoring the cementoenamel junction (cej) in class b grs before root coverage therapy yields comparable clinical and volumetric outcomes to class a grs with detectable cej. in addition, the influence of the cej restoration on dentin sensitivity and aesthetic satisfaction of the patient will be investigated. to our knowledge, it will be the first clinical study to use pini prato et al.'s surface discrepancy classification as a decision-making tool to guide periodontal-restorative procedures.

Eligibility criteria:
inclusion criteria: * systemically healthy individuals older than 18 years old; * healthy periodontal status according to the aap/efp definition; * full-mouth plaque (fmps) and bleeding scores (fmbs) ≤ 20%; * at least one facial rt1 gr in single-rooted teeth with a minimum depth of 2 mm, associated with a nccl; * no history of periodontal surgery at the experimental site(s). exclusion criteria: * pregnancy or lactation; * self-reported smoking ≥10 cigarettes/day; * metabolic diseases that negatively affect soft tissue healing (i.e., diabetes mellitus); * any medication that may interfere with wound healing; * prosthetic crown at experimental teeth; * ongoing orthodontic therapy.
ecological momentary assessment study of adolescents and young adults with type 1 diabetes (ema-t1d)

Conditions: Type 1 Diabetes

Summary: this single site investigator-initiated prospective observational study will enroll up to 150 participants 13-26 years of age with type 1 diabetes (t1d) and utilize ecological momentary assessment methods (ema) to examine associations between different diabetes psychological domains (distress, anxiety, and depression) in real-time on self-efficacy, self-management behaviors, and glycemic outcomes.


Eligibility criteria:
inclusion criteria: * diagnosis of type 1 diabetes for at least six months * fluent in spoken and written english * willing to carry around their mobile phone during the home monitoring period with daily access to cellular or wifi connectivity * willing to wear a continuous glucose monitor (cgm) device during the home monitoring period exclusion criteria: * any social or medical condition that would, in the opinion of the principal investigator (pi), prevent complete participation in the study or would pose significant hazard to the subject's participation * skin conditions or diseases that would interfere with the cgm sensor placement or accuracy (such as extensive psoriasis, extensive eczema, scarring, etc.) * scheduled x-ray, mri, ct scan, or high-frequency electrical heat (diathermy) treatment during the period of cgm wear (or any other activity that would necessitate cgm sensor or insulin pump removal) that cannot be scheduled around or accommodated within the study assessment windows * currently pregnant or plan to become pregnant during participation in the study
effect of a family-based cbt self-help intervention for adolescents with ocd

Conditions: Obsessive - Compulsive Disorder

Summary: the goal of this clinical trial is to learn if self-help book can be used to treat obsessive-compulsive disorder (ocd) in adolescents aged 10 to 17. the main questions it aims to answer are: can adolescents and their parents effectively reduce the severity of the obsessive-compulsive symptoms in adolescents who are already stably taking medications through self-help books? what are the characteristics of adolescents who are best suited to use self-help intervention book to treat obsessive-compulsive symptoms? researchers will compare the use of a self-help books plus medication with medication alone to see if the combination of the self-help intervention and drug treatment can improve the obsessive-compulsive symptoms of adolescents more effectively. participants will: * read one chapter of a self-help book and complete the corresponding exercise each week for 12 weeks * visit the clinic before and after intervention for checkups and tests


Eligibility criteria:
inclusion criteria: 1. age between 10 and 17 years 2. satisfied with the diagnostic criteria for ocd in dsm-5 3. 16≤cy-bocs score ≤23 4. taking medication stably for 6 weeks 5. education level ⩾6 years 6. at least one parent can accompany the patients throughout the entire intervention process 7. the patient and the participating parent have sufficient reading and writing skills to complete the treatment intervention 8. the patient and the participating parent have adequate auditory and visual abilities skills to complete the necessary examinations for the study (7) right-handed (this criterion is for fmri subjects only) (8) subjects and their guardians understood the study and signed informed consent. exclusion criteria: 1. obsessive-compulsive symptoms were too severe to participate in the experiment(cy-bocs score ≥24) 2. high risk of suicide 3. comorbid brain organic diseases, severe somatic diseases, learning disabilities, autism spectrum disorders, schizophrenia spectrum and other psychotic disorders, bipolar disorder, severe eating disorders, or substance abuse 4. completed a cognitive behavioral therapy (cbt) course for ocd within the past 12 months. 5. an iq lower than 80 6. currently undergoing other psychological/physical treatments 7. uncooperative or unable to complete treatment 8. with metal implants in the body, such as pacemakers, intracranial silver clips, metal dentures, arterial stents, arterial clips, joint metal fixation, or other metal implants, etc. (this criterion is for fmri subjects only)

Keywords: obsessive - compulsive disorder adolescents bibliotherapy
study to evaluate a single intranasal dose of sti-2099 (covi-drops™) in outpatient adults with covid-19 (us)

Conditions: Covid19

Summary: this is a double-blind study designed to investigate the efficacy, safety and pk of a single dose of covi-drops or matched placebo in outpatient adults who have tested positive for covid-19 and are either asymptomatic or have mild symptoms.

subjects will be randomized 1:1:1:1 to receive a single dose of covi-drops 10 mg, covi-drops 20 mg, covi-drops 40 mg, or placebo in a double-blind manner. investigational product (covi-drops or placebo) will be administered once on study day 1. subjects will be followed to day 60.

Eligibility criteria:
inclusion criteria: * positive for covid-19 with any approved rt-pcr or rapid antigen test within 7 days of planned treatment * either have no covid-19 symptoms (asymptomatic) or mild symptoms * must be willing and able to comply with all planned study procedures and be available for all study visits and follow-up as required by this protocol * subject must have provided written informed consent which includes signing the institutional review board or independent ethics committee approved consent form prior to participating in any study related activity * willing to follow contraception guidelines exclusion criteria: * in the investigator's opinion, has moderate or severe symptoms or rapidly progressive symptoms which are likely to progress such that a hospitalization is imminent (within 24-48 hours) * any medical condition that, in the investigator's opinion, could adversely impact safety or key objectives of the study, particularly any intranasal pathology or disease process. * has a documented infection other than covid-19 * pregnant or lactating women who are breast feeding or planning on either during the study * has participated or is participating in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * has a high risk of progressing to severe covid-19 per cdc's risk stratification (see: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html) * is an immunocompromised subject even if previously fully vaccinated against covid-19 or recovered from a prior covid-19 infection.

Keywords: covid-19
long-term follow up study for amd3100 patients

Conditions: Myeloma

Summary: objectives: the objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor \[amd3100\]) in protocol amd3100-3102. patients that received at least 1 dose of study treatment (placebo or plerixafor) in the multicenter, randomized, double-blind, placebo-controlled amd3100-3102 study, which was designed to evaluate plerixafor plus granulocyte colony stimulating factor (g-csf) versus placebo plus g-csf to mobilize hematopoietic stem cells for autologous transplantation of multiple myeloma (mm) patients are eligible.

informed consent process: your study doctor or staff will either meet with you in person or contact you by phone to review the study information. you will be given a copy of this consent form to review and ask questions. if you agree to take part in this study, you should sign this consent form on the date that you agree to be in the study. if you agree to take part during a phone call with a member of the study team, you should sign and date the form right away, on the date of the phone call, and mail the form to the study doctor or staff. please keep a copy for your own reference. 5-year follow-up: you will be contacted by phone or in person at a visit, every 6 months for 5 years from the time of your first study drug/placebo dose in the 2004-0982 study. a placebo is a substance that looks like the study drug but has no active ingredients. if you received a transplant in the 2004-0982 study, your first contact in this study will either be about 18 months from the time you began the 2004-0982 study, or at the time you sign this consent form. if you did not receive a transplant, your first contact in this study will be at the time you sign this consent form. at your first visit or call, you will be asked about the status of the disease, any changes in the multiple myeloma that may have occurred since the 2004-0982 study, and any additional treatments you may have received during that time. at every visit or call after that, you will be asked about the status of the multiple myeloma, any changes in the disease, and any treatments you have received since the last visit or call. these questionnaires will take about 10 minutes each time. your doctor or the study staff also may contact your local doctor in order to collect information from your medical records or for information about your medical history and disease status. length of study participation: you will be off study after your last study phone call or visit (about 5 years after your first study drug/placebo dose in the 2004-0982 study). this is an investigational study. up to 300 patients will participate in this multi-center study. up to 12 will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria: * 1) all patients who received the study drug (placebo or plerixafor) on protocol amd3100-3102 (2004-0982) exclusion criteria: none

Keywords: multiple myeloma disease-free survival amd3100 g-csf autologous transplantation
making decisions about the measles-mumps-rubella vaccine

Conditions: Measles; Mumps; Rubella; MMR Vaccination

Summary: the goal of this study is to determine whether a computer-based intervention that delivers individually-tailored educational messages about the mmr vaccine increases mmr vaccine-hesitant parents' intentions to have their children vaccinated.

this will be a randomized controlled intervention trial for mmr vaccine-hesitant parents of children ages six years and younger who have not yet received the mmr vaccine. parents will complete a three-item measure that assesses their baseline intentions for having their children vaccinated with mmr. participants will then fill out a short, computer-based survey that assesses demographic factors, prior experience with mmr, and views about a variety of potential barriers to mmr vaccination. following the survey, the intervention group (40 parents) will view a series of tailored educational messages resembling web pages that uses their survey data to address at an individual level their specific concerns about the mmr vaccine. the control group (40 parents) will view a series of generic educational messages resembling web pages that is similar in appearance to the intervention, but contains only untailored information about the vaccine. after navigating through these educational messages, mmr vaccination intention will be reassessed using the same three-item measure as for the baseline assessment of vaccination intention. the vaccine administration records of the children of these parents will be accessed after parents' participation in the study to assess whether the mmr vaccine was provided to the child.

Eligibility criteria:
inclusion criteria: * parent is greater than or equal to 18 years of age * parent has a child 6 years of age or younger * when asked to describe how he/she feels about getting child vaccinated against mmr, parent responds "i don't want to get my child vaccinated" or "i'm unsure if i want my child to get vaccinated" exclusion criteria: * cannot read/speak english

Keywords: measles mumps rubella mmr prevention tailoring persuasive communication children
data collection for the assessment of acute and late normal tissue in patients treated with proton therapy

Conditions: Breast Carcinoma; Esophageal Carcinoma; Genitourinary System Carcinoma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Lung Carcinoma; Malignant Central Nervous System Neoplasm; Malignant Digestive System Neoplasm; Malignant Solid Neoplasm

Summary: this study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. this may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.

primary objectives: i. to prospectively collect data on acute and late toxicities (including second malignant neoplasms) in patients treated with proton therapy. ii. to collect and store the corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution. secondary objectives: i. to derive and refine dose-response relationships for normal tissue toxicity after proton therapy. ii. to document and compare symptom burden weekly during treatment and twice a month for 3 months after therapy, using the m.d. anderson symptom inventory (mdasi). outline: patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.

Eligibility criteria:
inclusion criteria: * all patients scheduled for radiation treatment with protons at utmdacc are eligible for this protocol * patients must sign a study-specific consent form prior to study entry exclusion criteria: * patients who are unable or unwilling to attend the required periodic follow-ups either at m.d. anderson or at a different site
impact of acquired fxiii deficiency on morbidity and mortality

Conditions: Acquired Factor XIII Deficiency Disease

Summary: observational prospective study aiming to assess acquired fxiii deficiency implications in morbidity and mortality

all patients admitted to a large tertiary hospital with fxiii levels below 70% during their hospital stay are assessed. data regarding patient background, blood transfusion, morbidity and mortality is registered.

Eligibility criteria:
inclusion criteria: * fxiii levels \< 70% exclusion criteria: * none

Keywords: factor xiii blood transfusion mortality
study of urinary angiotensinogen as a marker to warn the deterioration of renal function in ckd patients early.

Conditions: Chronic Kidney Disease; Urinary Angiotensinogen

Summary: chronic kidney disease (ckd) that results in end-stage renal disease (esrd) is a major international health problem. many clinical markers such as urine protein or egfr(evaluated glomerular filtration rate),can estimate the renal function, but not sensitive. as well-known, the crucial role of angiotensin ii (angii), the major effector of the renin-angiotensin system (ras), in the development of renal fibrosis that results in esrd is widely recognized.abundant researches find that intrarenal ras takes an important role on the progression of ckd. at present, no clinical marker is available to evaluate intrarenal angii activity because it is difficult to measure it directly in patients. so find and establish a bio-marker of local renal ras activation maybe a breakthrough in early detection and treatment of ckd. angiotensinogen(agt) is the only known substrate for renin and the level of agt in humans is close to km value for renin. thus , changes in agt levels can control the activity of the ras, and its up-regulation may lead to activity of ang levels. then we hypothesis that the agt is a early bio-marker of local renal ras activation as well as ckd.

1. screening: select ckd(3-4) patients from outpatients, urine routine examination and renal b-mode ultrasonography and so on. 2. confirm: sign consent with the patients who meet the inclusion criteria, then these patients are included in the study. 3. create patients records and complete related-inspections. 4. clinical follow-up: follow-up once every six months, and we will record every patient's disease progress every time. each follow-up, the patient needs to leave 5 ml blood samples and 20 ml of urine samples, used for the following study. 5. detection, observation and evaluation: patients are divided into two groups according to agt levels: higher than the normal group and the normal group. observe the changes in egfr of different group. statistics judge whether agt can be as a early warning indicators of renal function decline.

Eligibility criteria:
inclusion criteria: * ckd, in the stage of 3 or 4, and kidney biopsy is preferred selection; * signed the informed consent; exclusion criteria: * kidney cancer patients; * kidney transplantation; * hereditary kidney disease; * secondary renal disease(diabetic nephropathy and hypertensive nephropathy are excluded)

Keywords: ckd ras agt
suprascapular nerve block with oral gabapentin for pain management in frozen shoulder

Conditions: Pain, Shoulder

Summary: the patients will be randomly allocated into two equal groups (each 20 patients) using sealed opaque numbered envelopes: control group (c group) : patients receive continuous us suprascapular nerve block only. gabapentin group (g group) : patients receive continuous us suprascapular nerve block with oral gabapentin 300 mg once daily at bed time. both groups compared as regard: visual analogue scale range of passive and active movements patients satisfaction complication related to block the total dose of diclofenac sodium


Eligibility criteria:
inclusion criteria: * body mass index ≥ 18 kg/m2 ≤ 30kg/m2 * asa i, ii or iii. * cooperative patients. exclusion criteria: * local infection at site of injection. * coagulopathy * previous history of mental disorders or chronic drug abuse (opioids, tranquilizers) * known hypersensitivity to any of the drugs used in the study.
evaluation of infective risk, efficacy of bacterial prophylaxis and validation of sepsis scores news (national early warning score) and qsofa (quick sequential organ failure assessment) in patient with acute myeloid leukemia treated with intensive chemotherapy

Conditions: Acute Myeloid Leukemia

Summary: evaluation of infective risk, efficacy of bacterial prophylaxis and validation of sepsis scores news (national early warning score) and qsofa (quick sequential organ failure assessment) in patient with acute myeloid leukemia treated with intensive chemotherapy


Eligibility criteria:
inclusion criteria: * diagnosis of non m3 acute myeloid leukemia according to who (world health organization) 2008 criteria * age \>= 18 years and \<= 70 years * patient had received intensive chemotherapy either as induction or consolidation regimen * period of observation: january 2001 - december 2019 * written informed consent exclusion criteria: * diagnosis of acute promyelocytic leukemia (m3 aml) * age \ 70 years * patient had not received intensive chemotherapy

Keywords: acute myeloid leukemia sepsis score national early warning score (news) quick sequential organ failure assessment (qsofa) chemotherapy-induced febrile neutropenia antibiotics prophylaxis